BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33644138)

  • 1. Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure.
    Zeng Q; Zhou Q; Liu W; Wang Y; Xu X; Xu D
    Front Cardiovasc Med; 2021; 8():636152. PubMed ID: 33644138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients.
    Balan I; Khayo T; Sultanova S; Lomakina Y
    Cureus; 2021 Aug; 13(8):e17118. PubMed ID: 34527497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure.
    Fadiran O; Nwabuo C
    Cureus; 2021 Nov; 13(11):e19379. PubMed ID: 34925982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 8. [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis].
    Kobalava ZD; Yeshniyazov NV; Medovchshikov VV; Khasanova ER
    Kardiologiia; 2019 Apr; 59(4):76-87. PubMed ID: 31002044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure-Current Evidence in Special Populations.
    Moady G; Ben Gal T; Atar S
    Life (Basel); 2023 May; 13(6):. PubMed ID: 37374037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review.
    Wahinya M; Khan Z
    Cureus; 2023 Apr; 15(4):e37388. PubMed ID: 37181972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 May; 17(1):74. PubMed ID: 29801492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus.
    Alkagiet S; Tziomalos K
    World J Diabetes; 2020 May; 11(5):150-154. PubMed ID: 32477451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK; Ghosh GC; Gupta M; Bandyopadhyay D; Akhtar T; Deedwania P; Lavie CJ; Fonarow GC; Aneja A
    Am J Cardiol; 2019 Dec; 124(11):1790-1796. PubMed ID: 31627834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 16. Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice.
    Rosano G; Quek D; Martínez F
    Card Fail Rev; 2020 Mar; 6():e31. PubMed ID: 33294215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Petrie MC; Filippatos GS; Anker SD; Rosano G; Bauersachs J; Paulus WJ; Komajda M; Cosentino F; de Boer RA; Farmakis D; Doehner W; Lambrinou E; Lopatin Y; Piepoli MF; Theodorakis MJ; Wiggers H; Lekakis J; Mebazaa A; Mamas MA; Tschöpe C; Hoes AW; Seferović JP; Logue J; McDonagh T; Riley JP; Milinković I; Polovina M; van Veldhuisen DJ; Lainscak M; Maggioni AP; Ruschitzka F; McMurray JJV
    Eur J Heart Fail; 2018 May; 20(5):853-872. PubMed ID: 29520964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis.
    Bhalla S; AlQabandi Y; Nandula SA; Boddepalli CS; Gutlapalli SD; Lavu VK; Abdelwahab Mohamed Abdelwahab R; Huang R; Potla S; Hamid P
    Cureus; 2022 Sep; 14(9):e29579. PubMed ID: 36312657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature.
    Abdelmasih R; Abdelmaseih R; Thakker R; Faluk M; Ali A; Alsamman MM; Hasan SM
    Cardiol Res; 2021 Aug; 12(4):210-218. PubMed ID: 34349861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.